Additionally, 300 μg of cotadutide demonstrated improvements in the lipid profile, AST and ALT levels, propeptide of the type III collagen level, fibrosis-4 index, and nonalcoholic fatty liver disease fibrosis score compared to the placebo group, but this effect was not observed with liraglutide. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.